We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resistance Training and Cardiometabolic Health

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03325933
Recruitment Status : Terminated (COVID-19)
First Posted : October 30, 2017
Last Update Posted : April 19, 2021
Sponsor:
Information provided by (Responsible Party):
Siddhartha Angadi, Arizona State University

Brief Summary:
This study will investigate the relationship between resistance training load and repetitions on cardiometabolic outcomes. The primary objective of this clinical trial is to determine whether high load or low load resistance exercise training affects arterial stiffness in overweight or obese men and women. Our secondary objectives are to investigate the effects of high and low load RT on vascular function, cardiac structure, and markers of insulin sensitivity. Finally, we are going to preliminarily explore the effects of resistance training on intestinal bacteria.

Condition or disease Intervention/treatment Phase
Insulin Sensitivity Endothelial Dysfunction Blood Pressure Other: High Load/Low Rep Resistance Training Other: Low Load/High Rep Resistance Training Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Resistance Training and Cardiometabolic Health
Actual Study Start Date : September 21, 2017
Actual Primary Completion Date : August 31, 2020
Actual Study Completion Date : August 31, 2020

Arm Intervention/treatment
Experimental: Resistance Training 1
Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
Other: High Load/Low Rep Resistance Training
Participants will be prescribed High Load/Low Rep resistance training.

Experimental: Resistance Training 2
Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
Other: Low Load/High Rep Resistance Training
Participants will be prescribed Low Load/High Rep resistance training.

No Intervention: Wait-list control
This group will be offered the option of participating in either experimental group after the study is completed.



Primary Outcome Measures :
  1. Arterial Stiffness [ Time Frame: Change from Baseline Pulse Wave Velocity at 12 weeks ]
    Measured via pulse wave velocity


Secondary Outcome Measures :
  1. Insulin Sensitivity [ Time Frame: Change from Baseline Matsuda Index at 12 weeks ]
    Measured via oral glucose tolerance testing (OGTT)

  2. Endothelial Function [ Time Frame: Change from Baseline %FMD at 12 weeks ]
    Measured via flow mediated dilation (FMD)

  3. Cardiac echocardiography [ Time Frame: Changes in systolic and diastolic parameters from baseline to 12 weeks ]
    Measured using ultrasound

  4. Isokinetic Strength [ Time Frame: Change from Baseline isokinetic strength at 12 weeks ]
    Measured via dynamometry

  5. Isometric Strength [ Time Frame: Change from Baseline Isometric strength at 12 weeks ]
    Measured via dynamometry

  6. Hexokinase [ Time Frame: Change from Baseline in insulin signalling proteins at 12 weeks ]
    Measured via skeletal muscle biopsies

  7. Insulin signaling proteins [ Time Frame: Change from Baseline in insulin signaling proteins at 12 weeks ]
    Measured via skeletal muscle biopsies

  8. Muscle Volume [ Time Frame: Change from Baseline Muscle Volume at 12 weeks ]
    Measured via ultrasonography

  9. Body Composition [ Time Frame: Change from Baseline body composition at 12 weeks ]
    Measured via Dual X-Ray Absorptiometry (DXA)

  10. Central Systolic Pressure [ Time Frame: Change from Baseline Central Systolic Pressure at 12 weeks ]
    Measured via Pulse Wave Analysis

  11. Central Diastolic Pressure [ Time Frame: Change from Baseline Central Systolic Pressure at 12 weeks ]
    Measured via Pulse Wave Analysis


Other Outcome Measures:
  1. Maximal Oxygen Consumption [ Time Frame: Change from Baseline VO2peak at 12 weeks ]
    Measured via VO2peak testing using an integrated metabolic system.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male and female
  • 18-55 years of age
  • BMI 25-40
  • No recent history of starting a structured exercise program or diet in the last 3 months

Exclusion Criteria:

  • Current smoker and/or recreational drug user
  • Answers "yes" to one or more questions on the Physical Activity Readiness Questionnaire
  • Diagnosed diabetes, heart disease
  • History of anabolic steroid use in the past six months
  • Taking medications for treatment of diabetes, heart disease, and hypertension.
  • Orthopedic or musculoskeletal contraindications to resistance training
  • Unwilling to follow any aspect of the study protocol including blood sampling and weight training

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03325933


Locations
Layout table for location information
United States, Arizona
Arizona State University
Phoenix, Arizona, United States, 85004
Sponsors and Collaborators
Arizona State University
Investigators
Layout table for investigator information
Principal Investigator: Siddhartha S Angadi, PhD Arizona State University
Publications:

Layout table for additonal information
Responsible Party: Siddhartha Angadi, Assistant Professor, Arizona State University
ClinicalTrials.gov Identifier: NCT03325933    
Other Study ID Numbers: STUDY00006617
First Posted: October 30, 2017    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: This data will be used primarily for a doctoral dissertation project as well as manuscript publication.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Siddhartha Angadi, Arizona State University:
insulin sensitivity
muscle
strength
resistance training
strength training
vascular function
arterial stiffness
glucose tolerance
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Hypersensitivity
Immune System Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases